LEADER 04748nam 2201153z- 450 001 9910557295103321 005 20231214133416.0 035 $a(CKB)5400000000041088 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69348 035 $a(EXLCZ)995400000000041088 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRadiolabelled Molecules for Brain Imaging with PET and SPECT 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (244 p.) 311 $a3-03936-720-X 311 $a3-03936-721-8 330 $aPositron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging methods which are widely used in nuclear medicine for diagnosis and treatment follow-up of many major diseases. These methods use target-specific molecules as probes, which are labeled with radionuclides of short half-lives that are synthesized prior to the imaging studies. These probes are called radiopharmaceuticals. The use of PET and SPECT for brain imaging is of special significance since the brain controls all the body?s functions by processing information from the whole body and the outside world. It is the source of thoughts, intelligence, memory, speech, creativity, emotion, sensory functions, motion control, and other important body functions. Protected by the skull and the blood?brain barrier, the brain is somehow a privileged organ with regard to nutrient supply, immune response, and accessibility for diagnostic and therapeutic measures. Invasive procedures are rather limited for the latter purposes. Therefore, noninvasive imaging with PET and SPECT has gained high importance for a great variety of brain diseases, including neurodegenerative diseases, motor dysfunctions, stroke, epilepsy, psychiatric diseases, and brain tumors. This Special Issue focuses on radiolabeled molecules that are used for these purposes, with special emphasis on neurodegenerative diseases and brain tumors. 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $aSV2A 610 $aSV2B 610 $aSV2C 610 $amicroPET 610 $a[18F]UCB-H 610 $aepilepsy 610 $aPBIF 610 $adistribution volume 610 $ablocking assay 610 $apreclinical imaging 610 $aAlzheimer?s disease (AD) 610 $anetwork measure 610 $agraph theory 610 $abrain network 610 $apositron emission tomography (PET) 610 $apersistent homology 610 $aPhosphodiesterase 2A (PDE2A) 610 $aPositron Emission Tomography (PET) 610 $aBenzoimidazotriazine (BIT) 610 $afluorinated 610 $aMouse Liver Microsomes (MLM) 610 $acyclic nucleotide phosphodiesterase 610 $aPDE2A radioligand 610 $anitro-precursor 610 $afluorine-18 610 $ain vitro autoradiography 610 $aPET imaging 610 $aopioid receptors 610 $apositron emission tomography 610 $aradiotracers 610 $a?OR-, ?OR-, ?OR- and ORL1-ligands 610 $amovement disorders 610 $apain 610 $adrug dependence 610 $aGBM 610 $abiomarkers 610 $aSigma 1 610 $aSigma 2 610 $aPD-L1 610 $aPARP 610 $aIDH 610 $aAlzheimer?s disease 610 $aParkinson?s disease 610 $a?-amyloid plaques 610 $aneurofibrillary tangles 610 $a?-synucleinopathy 610 $adiagnostic imaging probes 610 $aorexin receptors 610 $aPET 610 $aradiotracer 610 $aimaging 610 $aalpha 7 610 $anicotinic acetylcholine receptors 610 $anAChR 610 $aautoradiography 610 $aamino acid 610 $aFET 610 $aFACBC 610 $aFDOPA 610 $aimmunoPET 610 $amolecular imaging 610 $aglioma 610 $abrain metastases 610 $aadenosine A2A receptor 610 $arotenone-based mouse model 610 $a[18F]FESCH 610 $atwo-step one-pot radiosynthesis 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aBrust$b Peter$4edt$01291783 702 $aBrust$b Peter$4oth 906 $aBOOK 912 $a9910557295103321 996 $aRadiolabelled Molecules for Brain Imaging with PET and SPECT$93021916 997 $aUNINA